We are live on
!
Find out more
Alnylam Pharmaceuticals
ALNY
ALNY
487 hedge funds and large institutions have $28.3B invested in Alnylam Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 178 increasing their positions, 148 reducing their positions, and 85 closing their positions.
New
Increased
Maintained
Reduced
Closed
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
26% more call options, than puts
Call options by funds: $401M | Put options by funds: $318M
20% more repeat investments, than reductions
Existing positions increased: 178 | Existing positions reduced: 148
6% more capital invested
Capital invested by funds: $26.7B → $28.3B (+$1.61B)
1% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 85
2% less funds holding
Funds holding: 496 → 487 (-9)
14.46% less ownership
Funds ownership: 111.6% → 97.14% (-14%)
Holders
487
Holders Change
-9
Holders Change %
-1.81%
% of All Funds
7.83%
Holding in Top 10
14
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+27.27%
% of All Funds
0.23%
New
84
Increased
178
Reduced
148
Closed
85
Calls
$401M
Puts
$318M
Net Calls
+$82.8M
Net Calls Change
+$54M
Top Buyers
| 1 |
Capital World Investors
Los Angeles,
California
|
+$521M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$177M |
| 3 |
BlackRock
New York
|
+$175M |
| 4 |
JP Morgan Chase
New York
|
+$124M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$120M |
